Antibody-cytokine fusion proteins (also called "immunocytokines") represent an emerging class of biopharmaceutical products, which are being considered for cancer immunotherapy.
Introduction
Sarcomas represent an heterogenous group of malignancies that can originate from soft tissue, cartilage, bone and other connective tissues. In particular, soft tissue sarcomas are tumors, which stem from non-epithelial extra skeletal tissue (e.g. muscle, fat, blood vessels and others).
These cancer types are rare and they mainly affect young patients, however they represent 15% of all pediatric cancers [1] [2] [3] .
For small and localized tumors (i.e. in the limbs) surgical resection (sometimes combined with radiation) represents a curative therapy, however postsurgical recurrence is observed in 50% of patients. This treatment option is often not applicable for patients with metastatic disease or with tumors with a different histology (e.g. head, neck or abdomen) and in these cases, chemotherapy is administered as first-line treatment [4] . Doxorubicin represents the standardof-care for sarcomas with a response rate of 12-30% [5] . Doxorubicin may be combined with dacarbazine or other agents, however these combination treatments typically do not increase the survival benefit compared to the monotherapy [6] . Moreover, they are usually associated with substantial toxicities.
Already in the late 19 th century, William B Coley observed a case of a sarcoma patient who experienced a spontaneous tumor regression as a consequence of an erysipelas infection. This finding was the basis for the development of the "Coley's toxin", a mixture of heat-inactivated bacteria, which was found to increase the overall survival of sarcoma patients, in spite of the development of high fever and chill [7, 8] . It was later demonstrated that Coley's toxin treatment induced a dramatic increase of TNF levels [9] .
TNF is a homo-trimeric pro-inflammatory cytokine, mainly produced by macrophages, NK and T cells [10, 11] . TNF is involved in inflammatory processes and as indicated by its name, it may display a potent anticancer activity against some malignancies, by promoting hemorrhagic necrosis and by inducing direct apoptosis of tumor cells [12] [13] [14] [15] [16] [17] . Moreover, TNF may activate the immune system as a result of the increased inflammation [18] [19] [20] .
The systemic administration of recombinant human TNF (Beromun ® ) in the clinic is limited by substantial side effects and the maximal tolerated dose (MTD) was found to be 300µg/m 2 [21] .
Beromun® obtained marketing authorization only for locoregional treatments (i.e., for isolated limb perfusion procedure) in patients with soft-tissue sarcomas. The product is frequently administered in combination with melphalan [22] .
The use of recombinant cytokines for cancer therapy may cause substantial toxicities already at low doses, therefore limiting their clinical use and preventing escalation to therapeutically active dose regimens [23] [24] [25] [26] . To increase the therapeutic efficacy of cytokine payloads, the generation of fusion proteins with tumor-homing antibodies has been proposed. Antibodycytokine fusion proteins (also termed "immunocytokines") are capable of increasing the therapeutic index of the corresponding cytokine payload, as results of a selective localization at the site of disease [24] [25] [26] [27] [28] .
We have previously described the immunocytokine L19-mTNF, consisting of the fully human antibody fragment L19 (specific to the alternatively spliced EDB domain of fibronectin, a marker of angiogenesis) [29, 30] fused to murine TNF. The fusion protein was able to induce tumor regression in different murine cancer types either alone or in combination with chemotherapy or other immunocytokines [31] [32] [33] [34] [35] .
The fully human L19-TNF (featuring human TNF) has been investigated in cancer patients 
Materials and Methods
Cell lines and reagents CHO cells and WEHI-164 were obtained from the ATCC. Cell lines were received between 2017 and 2019, expanded, and stored as cryopreserved aliquots in liquid nitrogen. Cells were grown according the supplier's protocol and kept in culture for no longer than 14 passages.
Authentication of the cell lines also including check of postfreeze viability, growth properties, and morphology, test for mycoplasma contamination, isoenzyme assay, and sterility test were performed by the cell bank before shipment.
The production and purification of L19-mTNF was performed as described before [31] . 
Results and Discussion
In a first study, we compared the therapeutic activity of L19-mTNF, dacarbazine and trabectedin in immunocompetent BALB/c mice, bearing WEHI-164 sarcomas [Figure 1 ].
The treatment with saline and trabectedin alone, was not able to induce cancer regression. When used as single agents, L19-mTNF and trabectedin exhibited a mild tumor growth retardation compared to the saline group. Moreover, 25% of mice treated with L19-mTNF showed a complete response. By contrast, the combination therapy with these two agents led to an enhanced antitumor effect (75% of tumor eradication). Dacarbazine administered as a single agent showed the ability to cure 75% of the mice. This effect was further enhanced when administered in combination with L19-mTNF (100% complete response). [ Figure 1A , C]. All treatments were well tolerated as evidenced by the comparison of body weight profiles.
A transient toxicity was observed upon the first pharmacological treatment with the two combination treatments (L19-mTNF with either dacarbazine or trabectedin). However, all treated mice recovered the body weight loss in few days [ Figure 1B ].
In a second experiment, we compared the therapeutic activity of L19-mTNF in combination with melphalan or with an immune check-point inhibitor (anti-PD-1) in the same murine sarcoma model (WEHI-164) [Figure 2 ]. The therapeutic activity of L19-mTNF was enhanced when used in combination with either melphalan or with an anti-PD-1 antibody, respectively, 60% and 80% of the treated mice showed a complete response [Figure 2A , C]. All the treatments were well tolerated as evidenced by the comparison of body weight profiles [ Figure   2B ].
Conclusions
In this work, we presented a pre-clinical evaluation of combination modalities for the treatment of sarcoma lesions. The immunocytokine L19-mTNF was able to synergize with chemotherapeutic agents, which are already being considered for the treatment of sarcoma patients. Moreover, L19-mTNF was able to potentiate the anti-cancer activity of an anti-PD-1 antibody. The fully-human analog of L19-mTNF (L19-TNF), which is currently being 
